Website stats for Opdivo - opdivo.com
PROCEED TO SITE Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO. Please see U.S. Full Prescribing Information and Medication Guide for YERVOY. INDICATIONS AND IMPORTANT SAFETY INFORMATION Important Safety Information for OPDIVO (nivolumab) and OPDIVO + YERVOY (ipilimumab) What is the most important information I should know about OPDIVO + YERVOY? OPDIVO and YERVOY...
opdivo.com was registered 1 decade 2 years ago. It has a alexa rank of #853,255 in the world. It is a domain having .com extension. It is estimated worth of $ 1,440.00 and have a daily income of around $ 6.00. As no active threats were reported recently, opdivo.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 1,028 |
| Daily Pageviews: | 2,056 |
Estimated Valuation
| Income Per Day: | $ 6.00 |
| Estimated Worth: | $ 1,440.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 853,255 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
165.89.235.20
Hosted Country:
US
Location Latitude:
40.7453Location Longitude:
-73.9791Traffic Classification
| Total Traffic: | 199.11K |
| Direct Traffic: | 9.81% |
| Referral Traffic: | 5.81% |
| Search Traffic: | 66.67% |
| Social Traffic: | 0% |
| Mail Traffic: | 0% |
| Display Traffic: | 17.71% |
Search Engine Results For opdivo.com
OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. Read the indications, side effects, and more.
How OPDIVO® Works | OPDIVO® (nivolumab)
How Does OPDIVO® Work With My Immune System? · lung problems · intestinal ...
Advanced NSCLC | OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication for the treatment of adults with ... BOTH TYPES of ADVANCED NSCLC in clinical trials vs chemotherapy.
OPDIVO® Support & Patient Resources | OPDIVO® (nivolumab)
... OPDIVO® (nivolumab) patient, find resources that can offer support and ...
Advanced NSCLC First-Line Combination Therapy | OPDIVO ...
opdivo + Yervoy = A CHANCE FOR MORE BIG HUGS.
OPDIVO® Side Effects | OPDIVO® (nivolumab)
What Should I Know About Potential Side Effects? · diarrhea (loose stools) or ...
How Combination Therapy Works | OPDIVO® (nivolumab) + ...
OPDIVO® (nivolumab) + YERVOY® ( ipilimumab) work with your immune ...
OPDIVO® (nivolumab) | Information for Healthcare Professionals
Learn about OPDIVO® (nivolumab), a prescription medicine that treats certain types of cancers. Find the information you need to care for your OPDIVO® and ...
Nivolumab - Wikipedia
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell ...
Opdivo - Bristol Myers Squibb
OPDIVO as a single agent is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. • ...
OPDIVO® (nivolumab) Safety Tool | Healthcare Professionals
This safety tool is a quick reference to the immune-mediated adverse reactions associated with OPDIVO® treatment and OPDIVO®+YERVOY® (ipilimumab).
Opdivo (Nivolumab) for the Treatment of Different Types of Cancer
22 Jun 2020 ... Opdivo (nivolumab) is an immunotherapy by Bristol-Myers Squibb approved alone or in combination to treat various cancers, and under ...
FDA approves BMS' Opdivo and Yervoy combination in first-line ...
5 Oct 2020 ... The FDA has approved Opdivo (nivolumab) and Yervoy (ipilimumab), as the first and only immunotherapy for previously untreated unresectable ...
Nivolumab (Opdivo) with ipilimumab - NIHR Innovation Observatory
- http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/12568-Ipilimumab-with-nivolumab.pdf
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line. NIHRIO (HSRIC) ID: 12568. NICE ID: ...
Nivolumab (Opdivo®) - Macmillan Cancer Support
Nivolumab (Opdivo®) is an immunotherapy drug. It is used to treat different types of cancer. On this page. What ...
Int/Poor Risk Advanced Renal Cell Carcinoma | OPDIVO® (nivolumab)
OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated ...
Opdivo plus Yervoy combo approved in EU for first-line lung cancer ...
9 Nov 2020 ... Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) has received approval from the European Commission for the first-line ...
Nivolumab (Opdivo) Drug Information
Patients with melanoma that was completely removed by surgery. In such cases, Opdivo is used to help keep melanoma from coming back. Advanced lung cancer .
Opdivo (nivolumab) Cancer Medication - Cancer Health
5 Oct 2020 ... Opdivo (nivolumab) is a checkpoint inhibitor used in cancer immunotherapy.
Opdivo® | Immunotherapy For Mesothelioma - Mesothelioma Hub
6 Feb 2020 ... OPDIVO® is the brand name for the immunotherapy drug, nivolumab, used to treat small and non-small cell lung cancer and melanoma.
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | 1 | H2 Headings: | 2 |
| H3 Headings: | Not Applicable | H4 Headings: | 2 |
| H5 Headings: | 3 | H6 Headings: | Not Applicable |
| Total IFRAMEs: | Not Applicable | Total Images: | 85 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| people with | 94 | 1.038 % | No |
| is a | 77 | 0.851 % | No |
| OPDIVO® nivolumab | 76 | 0.84 % | No |
| medicine used | 71 | 0.784 % | No |
| prescription medicine | 71 | 0.784 % | No |
| a prescription | 71 | 0.784 % | No |
| nivolumab is | 71 | 0.784 % | No |
| to treat | 60 | 0.663 % | No |
| lung cancer | 60 | 0.663 % | No |
| with a | 53 | 0.586 % | No |
| combination with | 51 | 0.563 % | No |
| in combination | 51 | 0.563 % | No |
| a type | 50 | 0.552 % | No |
| treat people | 48 | 0.53 % | No |
| has spread | 47 | 0.519 % | No |
| type of | 46 | 0.508 % | No |
| used to | 43 | 0.475 % | No |
| years of | 43 | 0.475 % | No |
| of age | 43 | 0.475 % | No |
| of OPDIVO | 43 | 0.475 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| OPDIVO® nivolumab is a | 71 | 0.784 % | No |
| nivolumab is a prescription | 71 | 0.784 % | No |
| is a prescription medicine | 71 | 0.784 % | No |
| a prescription medicine used | 71 | 0.784 % | No |
| to treat people with | 48 | 0.53 % | No |
| prescription medicine used to | 43 | 0.475 % | No |
| medicine used to treat | 43 | 0.475 % | No |
| with a type of | 42 | 0.464 % | No |
| used to treat people | 35 | 0.387 % | No |
| used in combination with | 35 | 0.387 % | No |
| It is not known | 31 | 0.342 % | No |
| is not known if | 31 | 0.342 % | No |
| not known if OPDIVO | 31 | 0.342 % | No |
| in children younger than | 31 | 0.342 % | No |
| nonsmall cell lung cancer | 30 | 0.331 % | No |
| and effective in children | 29 | 0.32 % | No |
| safe and effective in | 29 | 0.32 % | No |
| effective in children younger | 29 | 0.32 % | No |
| known if OPDIVO is | 29 | 0.32 % | No |
| OPDIVO is safe and | 29 | 0.32 % | No |
Websites Hosted on Same IP (i.e. 165.89.235.20)
【肝炎.net】肝炎患者さんのための情報サイト
B型肝炎、C型肝炎について、基礎知識から最新のニュース、肝炎ウイルス検査の流れ、肝炎の原因、症状、病態、診断、治療法、予防法、検査値、用語など詳しい情報まで、総合的に解説しています。肝炎患者さんのための情報サイト【肝炎.net】
1,445,441 
$ 960.00
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Content-Type: text/html;charset=utf-8
Content-Length: 20048
Connection: keep-alive
Date: Wed, 23 Dec 2020 04:13:48 GMT
Server: Apache
X-Content-Type-Options: nosniff
Accept-Ranges: bytes
Content-Encoding: gzip
X-Dispatcher: dispatcher1useast1
X-Dispatcher-Number: 1
X-Vhost: publish
X-Frame-Options: SAMEORIGIN
Content-Security-Policy: frame-ancestors https://doctorunite.com https://generationnp.com https://paunite.com https://pathologistconnect.com https://oncologynation.com https://medicaldirectorsforum.com https://oncologynationsandbox.skipta.com https://www.opdivoclinicaldata.com https://www.opdivoyervoymnsclc.com; default-src https: blob: wss: 'unsafe-inline' 'unsafe-eval'; media-src https: blob:; font-src https: data:;
Strict-Transport-Security: max-age=63072000; includeSubDomains; preload
Cache-Control: max-age=0,s-maxage=0
Vary: Accept-Encoding,User-Agent
X-Cache: Miss from cloudfront
Via: 1.1 5d8c59c4e33ff30f6610982ac8ad0232.cloudfront.net (CloudFront)
X-Amz-Cf-Pop: FRA50-C1
X-Amz-Cf-Id: WT6x4eitcbInw7COGI56X3959yqMvRG6LIqVRigqlbNjxzfaP0pzDg==
Domain Information
| Domain Registrar: |
CSC Corporate Domains, Inc.
|
|---|---|
| Registration Date: | 2012-11-06 1 decade 2 years 1 week ago |
| Last Modified: | 2020-11-02 4 years 2 weeks 5 days ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| ns1.bms.com | |
198.155.167.250 | United States |
| ns2.bms.com | |
198.155.167.248 | United States |
| ns3.bms.com | |
198.155.223.8 | United States |
| ns4.bms.com | |
158.117.22.129 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| opdivo.com | A | 86377 |
IP: 165.89.235.20 |
| opdivo.com | NS | 86400 |
Target: ns4.bms.com |
| opdivo.com | NS | 86400 |
Target: ns1.bms.com |
| opdivo.com | NS | 86400 |
Target: ns3.bms.com |
| opdivo.com | NS | 86400 |
Target: ns2.bms.com |
| opdivo.com | SOA | 86400 |
MNAME: ns1.bms.com RNAME: dnsadmin.bms.com Serial: 2011111411 Refresh: 10800 Retry: 3600 Expire: 604800 |
| opdivo.com | TXT | 86400 |
TXT: facebook-domain-verification=h8n9cmmt24p 3sg3qkb31atgho5kbmv |
Top Organic Keyword
| 1. | opdivo |
| 2. | opdivo and yervoy |
| 3. | nivolumab |
| 4. | opdivo yervoy |
| 5. | opdivo success |
Top Paid Keyword
| 1. | opdivo |
| 2. | what is lung cancer |
| 3. | opdivo and yervoy |
| 4. | lung cancer |
| 5. | nivolamib |
Top Referral Site
| 1. | m3-c.pmsrv.co |
| 2. | stream.nbcsports.com |
| 3. | m1-c.pmsrv.co |
| 4. | m2-c.pmsrv.co |
Top Destination Site
| 1. | patientsupport.bmscustomerconnect.com |
| 2. | packageinserts.bms.com |
Full WHOIS Lookup
Registry Domain ID:
1757334616_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.corporatedomains.com
Registrar URL:
http://www.cscglobal.com/global/web/csc/digital-brand-services.html
Creation Date:
2012-11-06T02:19:18Z
Registry Expiry Date:
2021-11-06T02:19:18Z
Registrar: CSC Corporate Domains,
Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
8887802723
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Name Server:
NS1.BMS.COM
Name Server: NS2.BMS.COM
Name Server:
NS3.BMS.COM
Name Server: NS4.BMS.COM
DNSSEC: unsigned
URL
of the ICANN Whois Inaccuracy Complaint Form:
https://www.icann.org/wicf/
>>> Last update of whois database:
2020-12-23T04:13:53Z
Similarly Ranked Websites
هموطن کارت | استخرکارت | تخفیف کارت ا کارت رفاهی
کارت تخفیف هموطن تخفیف استخرهاو دندانپزشکی و ...با استفاده نامحدود،استخرکارت،استخر کارت
853,258 $ 1,440.00
AgoraEuFalo Academy - Como Aprender Inglês
Um novo conceito em técnicas muito simples de como aprender Inglês sozinho ou com acompanhamento.
853,261 $ 1,440.00
iDevAffiliate - Affiliate Tracking Software - Affiliate Program...
iDevAffiliate affiliate software provides you with affordable affiliate program software for you to start your affiliate tracking! Inexpensive affiliate software!
853,267 $ 1,440.00
Сайт о дизайне, фотошопе и графике,...
Фотошоп рамки, календари, фотокниги и виньетки можно скачать бесплатно – реализуем любой...
853,269 $ 1,440.00